Last updated on May 2017

Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Brief description of study

This study is designed to evaluate PFS endpoint for acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia.

Clinical Study Identifier: NCT02477696

Contact Investigators or Research Sites near you

Start Over

Acerta Pharma

Harvey, IL United States
  Connect »